Completed PHASE4 INTERVENTIONAL NCT00391261

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

A Prospective Open-label Trial of Metformin for Weight Control of Pediatric Patients on Atypical Antipsychotic Medications.

Sponsor: American Psychiatric Association

Conditions Autism Spectrum Disorders Bipolar Disorder Schizoaffective Disorder Schizophrenia Schizophreniform Disorder

Interventions Metformin

Updated 6 times since 2017 Last updated: Mar 24, 2010 Started: Jul 31, 2006 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Autism Spectrum Disorders and Bipolar Disorder, this trial is completed. The trial is conducted by American Psychiatric Association and has accumulated 6 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Psychiatric Association
Cambridge Health Alliance

Data source: Cambridge Health Alliance

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medford, United States